Tokyo, Japan, October 15, 2012—IFC,
a member of the World Bank Group, has presented Hikma Pharmaceuticals with
its 2012 Client Leadership Award which recognizes companies that show a
commitment to sustainable development, innovation, operational excellence,
and strong corporate governance.
IFC CEO and Executive Vice President Jin-Yong Cai presented the award to
Mazen Darwazah, Hikma Vice Chairman and CEO of the Middle East and North
Africa region, during a ceremony in Tokyo. Headquartered in Jordan, Hikma
has more than 6,500 employees and sales in some 50 countries. The Middle
East’s biggest pharmaceutical manufacturer, it was recognized for providing
affordable, life-saving medicine to people around the world. It was also
lauded for its strong corporate governance and internal efforts that support
female workers, encourage recycling, and provide internships to young Jordanians.
“This is award is a testament to the work we have done over the last 30
years to turn Hikma into a world-class company,” said Darwazah. “I think
it also shows that companies that focus on being good corporate citizens
will also have success.”
IFC has a long-term relationship with Hikma. Since 1987, IFC has invested
$165 million in the company, a total that includes both loans and share
purchases. It has also provided Hikma with advice in areas from corporate
governance to environmental management.
“Hikma is not only providing affordable medicines to millions—it is also
setting the standard for corporate social responsibility in the Middle
East and North Africa,” Cai said. “Our partnership of more than 20 years
with Hikma demonstrates how the private sector can spark change in the
region and make a difference in people’s lives.”
The partnership with Hikma is part of IFC’s efforts in the Middle East
and North Africa to encourage development by supporting the private sector.
Our investments reached a record $2.9 billion during the last fiscal year,
including $754 million in mobilization. We also launched 27 advisory projects
with a total value of $20.2 million.
IFC, a member of the World Bank Group is the largest global development
institution focused exclusively on the private sector. We help developing
countries achieve sustainable growth by financing investment, mobilizing
capital in international financial markets, and providing advisory services
to businesses and governments. In FY12, our investments reached an all-time
high of more than $20 billion, leveraging the power of the private sector
to create jobs, spark innovation, and tackle the world’s most pressing
development challenges. For more information, visit www.ifc.org.
Hikma Pharmaceuticals PLC is a fast growing multinational group focused
on developing, manufacturing, and marketing a broad range of both branded
and non-branded generic and licensed products. Hikma's operations
are conducted through three businesses: Branded, Injectables, and Generics.
It is based principally in the Middle East and North Africa , where it
is a market leader, the United States, and Europe. In 2011, Hikma achieved
revenues of $918 million and a profit attributable to shareholders of $80.3
million. For more information, visit www.hikma.com.